These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 8814850)

  • 1. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
    Abbas F; Kaplan M; Soloway MS
    Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
    Soloway MS; Hachiya T; Civantos F; Murphy WM; Gomez CC; Ruiz HE
    Urology; 1994 Feb; 43(2 Suppl):52-6. PubMed ID: 7509535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
    Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
    Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
    Meyer F; Bairati I; Bédard C; Lacombe L; Têtu B; Fradet Y
    Urology; 2001 Aug; 58(2 Suppl 1):71-7. PubMed ID: 11502453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up.
    Hajili T; Ohlmann CH; Linxweiler J; Niklas C; Janssen M; Siemer S; Stoeckle M; Saar M
    BJU Int; 2019 Jan; 123(1):58-64. PubMed ID: 29772100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
    Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
    Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
    Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
    Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
    Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
    Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
    Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
    Kiriyama I; Ogaki K; Ohba S; Nishimura T
    J Nippon Med Sch; 2002 Oct; 69(5):422-7. PubMed ID: 12382001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen.
    Soloway MS; Hachiya T; Ruiz HE; Gomez CC; Civantos F
    World J Urol; 1993; 11(4):221-6. PubMed ID: 7508788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
    Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
    J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.